Buscar
Congreso SOLACI
HomeCoronary diseaseDrug-eluting stents

Drug-eluting stents

Ver Categoría

Coronary disease

DES and DCB with Similar Results in Femoropopliteal Artery Disease

Courtesy of Dr. Carlos Fava. Nowadays, peripheral interventions are on the rise and the technological development of stents and...
solaci -
Ver más
Coronary disease

Drug eluting Stents vs. Drug Coated Balloons for In-Stent Restenosis

The rationale behind the decision to not add another layer of metal to the artery sounded attractive...
solaci -
Ver más
Coronary disease

Outcomes of Contemporary DES in Patients with Diabetes: Do They Render Freedom Obsolete?

Despite our high hopes for new-generation drug-eluting stents (DES), patients with diabetes still have a different prognosis,...
solaci -
Ver más
Coronary disease

Everolimus-Eluting Stents Finally Have a Rival and Not Just a “Non-Inferior” Stent

In this large randomized trial, there were significant differences as regards both target-lesion failure and target-vessel-related infarction,...
solaci -
Ver más
Coronary disease

Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference

Patients with infrarenal abdominal aortic aneurysm (AAA) and ≥ 30 mm neck diameter have 3 times higher...
solaci -
Ver más
Coronary disease

Early Strut Coverage and Its Implications for Dual Antiplatelet Therapy

Optical coherence tomography (OCT)-guided drug-eluting stent implantation improves early strut coverage compared with angiography-guided angioplasty. No difference...
solaci -
Ver más
Coronary disease

AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer

Sirolimus-eluting stents with biodegradable polymer did not offer better outcomes compared with instant-classic (and undoubtedly valid) everolimus-eluting...
solaci -
Ver más
Coronary disease

TCT 2018 | ABSORB IV: Much Life Left for Bioresorbable Scaffolds

Previous studies have documented higher rates of adverse events with bioresorbable scaffolds (ABSORB) compared with metallic drug-eluting...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Dr. Omar Tupayachi - 0
Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Dr. Juan Manuel Pérez - 0
Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Dr. Andrés Rodríguez - 0
Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

Noticias Institucionales

Fellow’s Corner 2026 – Submit Your Clinical Case

solaci - 0
Share your experience. Learn from experts. Grow as an interventional cardiologist. The Latin American Society of Interventional Cardiology (SOLACI) is relaunching this year the Fellow’s...

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

solaci - 0
The webinar “Cardiovascular Risk Factors in Women,” held on January 27, 2026, via the Zoom platform, is now available for viewing on SOLACI’s YouTube...

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

solaci - 0
The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad